Demant Cash Flow from Operating Activities 2012-2024 | WILYY

Demant cash flow from operating activities for the twelve months ending December 31, 2024 was $1.865B, a 43.6% increase year-over-year.

  • Demant annual cash flow from operating activities for 2024 was $0.592B, a 6.01% decline from 2023.
  • Demant annual cash flow from operating activities for 2023 was $0.629B, a 69.54% increase from 2022.
  • Demant annual cash flow from operating activities for 2022 was $0.371B, a 28.75% decline from 2021.

Demant Cash Flow from Operating Activities 2012-2024 | WILYY

  • Demant annual cash flow from operating activities for 2024 was $0.592B, a 6.01% decline from 2023.
  • Demant annual cash flow from operating activities for 2023 was $0.629B, a 69.54% increase from 2022.
  • Demant annual cash flow from operating activities for 2022 was $0.371B, a 28.75% decline from 2021.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$230.8B
Boston Scientific (BSX)$157.3B
Stryker (SYK)$150.7B
EssilorLuxottica (ESLOY)$147.8B
Medtronic (MDT)$118.8B
Lonza Group Ag (LZAGY)$49.6B
Haleon (HLN)$44B
ResMed (RMD)$43B
Agilent Technologies (A)$34.6B
GE HealthCare Technologies (GEHC)$34.3B
Terumo (TRUMY)$27.7B
Koninklijke Philips (PHG)$27.3B
Insulet (PODD)$23.3B
Zimmer Biomet Holdings (ZBH)$21.3B
Smith & Nephew SNATS (SNN)$16.4B
Baxter (BAX)$12.6B
Sunny Optical Technology (SNPTF)$10.8B
Bio-Rad Laboratories (BIO)$8.2B
Lantheus Holdings (LNTH)$4B
Envista Holdings (NVST)$3.6B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Perrigo (PRGO)$3.4B
Prestige Consumer Healthcare (PBH)$3.3B
ICU Medical (ICUI)$3.2B
Haemonetics (HAE)$2.7B
LeMaitre Vascular (LMAT)$2.3B
Acuren (TIC)$2.1B
QuidelOrtho (QDEL)$1.9B
Curaleaf Holdings (CURLF)$1.9B
AtriCure (ATRC)$1.9B